UK – Revlimid gets NICE nod for lymphoma

The National Institute for Health and Care Excellence (NICE) has announced a new treatment option for patients with previously treated follicular lymphoma, bringing a new option to the market for around 900 patients.

Celgene’s Revlimid (lenalidomide) has been recommended by the health body in combination with Roche’s MabThera (rituximab) for grade one to three variations of the disease. The drug in question works by fighting cancer cells in a different way to current treatments, by interfering with cell processes to halt the growth of tumours and stopping them from producing their own blood vessels.

The decision was based on clinical trial evidence showing that taking lenalidomide with rituximab increases the length of time before the disease progresses by around 39.4 months, compared to around 13.8 months when taking rituximab alone…